Improved discrimination of AD patients using β-amyloid((1-42)) and tau levels in CSF

Neurology

Volumn 52, Issue 8, 1999, Pages 1555-1562

  Hulstaert, Frank ^a   Blennow, K ^j   Ivanoiu, A ^b   Schoonderwaldt, H C ^e   Riemenschneider, M ^f   De Deyn, P P ^c   Bancher, C ^h   Cras, P ^d   Wiltfang, J ^g   Mehta, P D ^j   Iqbal, K ⁱ   Pottel, H ^a   Vanmechelen, E ^a   Vanderstichele, H ^a  

^a INNOGENETICS   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

^h GENERAL HOSPITAL LINZ   (Austria)

ⁱ NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN CONTENT;

EID: 0033549069     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.8.1555     Document Type: Article

References (31)

1. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Consensus report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease. Neurobiol Aging 1998; 19:109-116.
2. (1-42) in Alzheimer's disease: differences between early- and late-onset AD and stability during the course of disease. Arch Neurol 1999 (in press).
3. 4(1-42)] in CSF. In: Fisher A, Hanin I, Yoshida M, eds. Progress in Alzheimer's and Parkinson's diseases. New York: Plenum Press, 1998:773-778.
4. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of τ proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993;61:1828-1834.
5. Van de Voorde A, Vanmechelen E, Vandermeeren M, Dessaint F, Beeckman W, Cras P, Detection of tau in cerebrospinal fluid. In: Iqbal K, Mortimer JA, Winblad B, Wisniewski HM, eds. Research advances in Alzheimer's disease and related disorders. Chichester: John Wiley & Sons Ltd., 1995:189-195.
6. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231-245.
7. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994;142-143.
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadian EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
10. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992;42: 473-480.
11. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43: 250-260.
12. The Lund and Manchester Groups. Consensus statement. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994;57:416-418.
13. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. Belmont, CA: Wadsworth International Group, 1984.
14. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
15. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998;55:937-945.
16. Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998;44: 17-26.
17. 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38:643-648.
18. Andreasen N, Vanmechelen E, Van de Voorde A, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community-based follow-up study. J Neurol Neurosurg Psychiatry 1998;64:298-305.
19. Mayeux R. Evaluation and use of diagnostic tests in Alzheimer's disease. Neurobiology Aging 1998;19:139-143.
20. Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci Lett 1996;212:209-211.
21. Galasko D, Clark C, Chang L, et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology 1997;48:632-635.
22. Goedert M, Jakes R, Spillantini MG, et al. Tau protein in Alzheimer's disease. Biochem Soc Trans 1995;23:80-85.
23. Khatoon S, Grundke-Iqbal I, Iqbal K. Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains. FEBS Lett 1994;351:80-84.
24. Otto M, Wiltfang J, Tumani H, et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 1997;225:210-212.
25. Vanderstichele H, Van Gool S, Brock P, et al. Monitoring of chemotherapy-induced neurotoxicity in children using CSF markers, a longitudinal study. Neurobiol Aging 1998;19:S168. Abstract.
26. Tamaoka A, Sawamura N, Fukushima T, et al. Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci 1997;148:41-45.
27. Jellinger KA. Diagnostic accuracy of Alzheimer's disease: a clinicopathological study. Acta Neuropathol 1996;91:219-220.
28. Kosunen O, Soininen H, Paljärvi L, Heinonen O, Talasniemi S, Riekkinen PJ Sr. Diagnostic accuracy of Alzheimer's disease: a neuropathological study. Acta Neuropathol 1996;91: 185-193.
29. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:9649-9653.
30. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993;11:575-580.
31. (1-42) in cerebrospinal fluid from Alzheimer's disease patients and controls. Neurobiol Aging 1998;19:S163. Abstract.